

CDK1/CyclinA2, Active

Full-length recombinant protein expressed in Sf9 cells

Catalog # C22-18G-10

Lot # Q173-1

Product Description

Recombinant full-length human CDK1 and CyclinA2 were co-expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag on both proteins. The CDK1 gene accession number is [NM_001786](#); CyclinA2 is [NM_001237](#).

Gene Aliases

CDK1: CDC2, CDC28A, MGC111195, DKFZp686L20222

CyclinA2: CCN1, CCNA

Concentration

0.1 µg/µl

Formulation

Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

Storage , Shipping and Stability

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Stability is 1yr at -70°C from date of shipment. Product shipped on dry ice.

Scientific Background

CDK1 or Cell Division Control protein 1 is essential for the completion of START, the controlling event in the cell cycle that is required to initiate mitosis. CDK1 is a catalytic subunit of a protein kinase complex, called the M-Phase Promoting Factor that induces entry into mitosis and is universal among eukaryotes (1). Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer has also been demonstrated (2).

References

1. Vantieghe, A. et al: Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. *J. Biol. Chem.* 2002; 277(40):37718-31.
2. Rigas, A.C. et al: Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer. *Oncogene.* 2007; 18.

Purity





Figure 1. SDS-PAGE gel image

The purity of CDK1/CyclinA2 was determined to be **>70%** by densitometry, CDK1 approx. MW **59kDa** and CyclinA2 Approx. MW **78kDa**.


Specific Activity

Figure 2. Radiometric Assay Data



The specific activity of CDK1/CyclinA2 was determined to be **205 nmol /min/mg** as per activity assay protocol. (For Radiometric Assay Protocol on this product please see pg. 2)

Figure 3. ADP- Glo™ Assay Data



The specific activity of CDK1/CyclinA2 was determined to be **272 nmol /min/mg** as per activity assay protocol. (For ADP-Glo™ Assay Protocol on this product please see pg. 3)

Activity Assay Protocol

Reaction Components

Active Kinase (Catalog #: C22-18G-10)

Active CDK1/CyclinA2 (0.1 μ g/ μ l) diluted with Kinase Dilution Buffer III (Catalog #: K23-09) and assayed as outlined in sample activity plot. (Note: these are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active CDK1/CyclinA2 for optimal results).

Kinase Dilution Buffer III (Catalog #: K23-09)

Kinase Assay Buffer I (Catalog #: K01-09) diluted at a 1:4 ratio (5X dilution) with distilled H₂O.

Kinase Assay Buffer I (Catalog #: K01-09)

Buffer components: 25mM MOPS, pH 7.2, 12.5mM β -glycerol-phosphate, 25mM MgCl₂, 5mM EGTA, 2mM EDTA. Add 0.25mM DTT to Kinase Assay Buffer prior to use.

[³³P]-ATP Assay Cocktail

Prepare 250 μ M [³³P]-ATP Assay Cocktail in a designated radioactive working area by adding the following components: 150 μ l of 10mM ATP Stock Solution (Catalog #: A50-09), 100 μ l [³³P]-ATP (1mCi/100 μ l), 5.75ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 1ml aliquots at -20°C.

10mM ATP Stock Solution (Catalog #: A50-09)

Prepare ATP stock solution by dissolving 55mg of ATP in 10ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 200 μ l aliquots at -20°C.

Substrate (Catalog #: H10-54N)

Histone H1 diluted in 50mM Tris-HCl, pH 7.5, and 150mM NaCl buffer to a final concentration of 1mg/ml.

Assay Protocol

- Step 1.** Thaw [³³P]-ATP Assay Cocktail in shielded container in a designated radioactive working area.
- Step 2.** Thaw the Active CDK1/CyclinA2, Kinase Assay Buffer, Substrate and Kinase Dilution Buffer on ice.
- Step 3.** In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20 μ l:
 - Component 1.** 10 μ l of diluted Active CDK1/CyclinA2 (Catalog #C22-18G-10)
 - Component 2.** 5 μ l of 1mg/ml stock solution of substrate (Catalog #H10-54N)
 - Component 3.** 5 μ l distilled H₂O (4°C)
- Step 4.** Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled H₂O.
- Step 5.** Initiate the reaction by the addition of 5 μ l [³³P]-ATP Assay Cocktail bringing the final volume up to 25 μ l and incubate the mixture in a water bath at 30°C for 15 minutes.
- Step 6.** After the 15 minute incubation period, terminate the reaction by spotting 20 μ l of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
- Step 7.** Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (dilute 10ml of phosphoric acid and make a 1L solution with distilled H₂O) with constant gentle stirring. It is recommended that the strips be washed a total of 3 intervals for approximately 10 minutes each.
- Step 8.** Count the radioactivity (cpm) on the P81 paper in the presence of scintillation fluid in a scintillation counter.
- Step 9.** Determine the corrected cpm by removing the blank control value (see Step 4) for each sample and calculate the kinase specific activity as outlined below.

Calculation of [³³P]-ATP Specific Activity (SA) (cpm/pmol)

Specific activity (SA) = cpm for 5 μ l [³³P]-ATP / pmoles of ATP (in 5 μ l of a 250 μ M ATP stock solution, i.e., 1250 pmoles)

Kinase Specific Activity (SA) (pmol/min/ μ g or nmol/min/mg)

Corrected cpm from reaction / [(SA of ³³P-ATP in cpm/pmol)*(Reaction time in min)*(Enzyme amount in μ g or mg)]*[(Reaction Volume) / (Spot Volume)]

ADP-Glo™ Activity Assay Protocol

Reaction Components

CDK1/CyclinA2 Kinase Enzyme System (Promega, Catalog #:V2961)

CDK1/Cyclin A2, Active, 10µg (0.1µg/µl)
Histone H1, substrate, 1ml (1mg/ml)
Reaction Buffer A (5X), 1.5ml
DTT solution (0.1M), 25µl

ADP-Glo™ Kinase Assay Kit (Promega, Catalog #: V9101)

Ultra Pure ATP, 10 mM (0.5ml)
ADP, 10 mM (0.5ml)
ADP-Glo™ Reagent (5ml)
Kinase Detection Buffer (10ml)
Kinase Detection Substrate (Lyophilized)

Reaction Buffer A (5X)

200mM Tris-HCl, pH 7.5, 100mM MgCl₂ and 0.5 mg/ml BSA.

Assay Protocol

The CDK1/CyclinA2 assay is performed using the CDK1/CyclinA2 Kinase Enzyme System (Promega; Catalog #: V2961) and ADP-Glo™ Kinase Assay kit (Promega; Catalog #: V9101). The CDK1/CyclinA2 reaction utilizes ATP and generates ADP. Then the ADP-Glo™ Reagent is added to simultaneously terminate the kinase reaction and deplete the remaining ATP. Finally, the Kinase Detection Reagent is added to convert ADP to ATP and the newly synthesized ATP is converted to light using the luciferase/luciferin reaction. For more detailed protocol regarding the ADP-Glo™ Kinase Assay, see the technical Manual #TM313, available at www.promega.com/tbs/tm313/tm313.html.

- Step 1.** Thaw the ADP-Glo™ Reagents at ambient temperature. Then prepare Kinase Detection Reagent by mixing Kinase Detection Buffer with the Lyophilized Kinase Detection Substrate. Set aside.
- Step 2.** Thaw the components of CDK1/CyclinA2 Enzyme System, ADP and ATP on ice.
- Step 3.** Prepare 1ml of 2X Buffer by combining 400µl Reaction Buffer A, 1µl DTT and 599µl of dH₂O.
- Step 4.** Prepare 1ml of 250µM ATP Assay Solution by adding 25µl ATP solution (10mM) to 500µl of 2X Buffer and 475µl of dH₂O.
- Step 5.** Prepare diluted CDK1/CyclinA2 in 1X Buffer (diluted from 2X buffer) as outlined in sample activity plot. (Note: these are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active CDK1/CyclinA2 for optimal results).
- Step 6.** In a white 96-well plate (Corning Cat # 3912), add the following reaction components bringing the initial reaction volume up to 20µl:

Component 1.	10µl of diluted Active CDK1/CyclinA2
Component 2.	5µl of 1mg/ml stock solution of substrate
Component 3.	5µl of 2X Buffer
- Step 7.** Set up the blank control as outlined in step 6, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled H₂O.
- Step 8.** At the same time as the CDK1/CyclinA2 kinase reaction, set up an ATP to ADP conversion curve at 50µM ATP/ADP range as described in the ADP-Glo™ Kinase Assay technical Manual #TM313.
- Step 9.** Initiate the CDK1/CyclinA2 reactions by the addition of 5µl of 250 µM ATP Assay Solution thereby bringing the final volume up to 25µl. Shake the plate and incubate the reaction mixture at 30°C for 15 minutes.
- Step 10.** Terminate the reaction and deplete the remaining ATP by adding 25µl of ADP-Glo™ Reagent. Shake the 96-well plate and then incubate the reaction mixture for another 40 minute at ambient temperature.
- Step 11.** Add 50µl of the Kinase Detection Reagent, shake the plate and then incubate the reaction mixture for another 30 minute at ambient temperature.
- Step 12.** Read the 96-well reaction plate using the Kinase-Glo™ Luminescence Protocol on a GloMax® Microplate Luminometer (Promega; Cat # E6501).
- Step 13.** Using the conversion curve, determine the amount of ADP produced (nmol) in the presence (step 6) and absence of substrate (Step 7) and calculate the kinase specific activity as outlined below. For a detailed protocol of how to determine nmols from RLUs, see ADP-Glo™ Applications Database at <http://www.promega.com/applications/cellularanalysis/cellsignaling.htm>

Kinase Specific Activity (SA) (nmol/min/mg)

(ADP (step 6) – ADP (Step 7)) in nmol / (Reaction time in min)*(Enzyme amount in mg)